Is homozygosity for the HR2 haplotype a risk factor for venous thromboembolism?

Thrombosis and Haemostasis

Volumn 87, Issue 1, 2002, Pages 173-174

  Aras, Omer ^a   Hanson, Naomi Q ^a   Tsai, Michael Y ^a   Key, Nigel S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADOLESCENT; ALLELE; CASE REPORT; CAVA VEIN DISEASE; DEEP VEIN THROMBOSIS; EXON; GENE MUTATION; HAPLOTYPE; HOMOZYGOSITY; HUMAN; LETTER; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0036145792     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612965     Document Type: Letter

References (8)

1. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma
2. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
3. The factor V gene A4070G mutation and the risk of venous thrombosis
4. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C
5. The HR2 haplotype of factor V: Effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis
6. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden)
7. Prospective study of venous thromboembolism in relation to factor V Leiden and related factors: The Longitudinal Investigation of Thromboembolism Etiology (LITE)
8. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma